Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer’s Disease

Reuters

2025/12/08

Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer's Disease

Arrowhead Pharmaceuticals Inc. announced the initiation of a Phase 1/2a clinical trial for ARO-MAPT, an investigational RNA interference (RNAi) therapeutic targeting tauopathies, including Alzheimer's disease. ARO-MAPT utilizes Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform, designed for subcutaneous administration and systemic delivery to the central nervous system by crossing the blood-brain barrier. In preclinical studies presented at the RNA Leaders USA Congress 2025, ARO-MAPT demonstrated potent and sustained suppression of microtubule associated protein tau $(MAPT)$ mRNA and tau protein in non-human primates. The company indicates that these results may enable monthly or quarterly dosing with uniform CNS distribution. Presentation slides are available on the Arrowhead website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208566889) on December 08, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2589330083"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2589330083\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2589330083?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589330083","market":"nz","top_or_hot":-1,"title":"Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer’s Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer's Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arrowhead Pharmaceuticals Inc. announced the initiation of a Phase 1/2a clinical trial for ARO-MAPT, an investigational RNA interference (RNAi) therapeutic targeting tauopathies, including Alzheimer's disease. ARO-MAPT utilizes Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform, designed for subcutaneous administration and systemic delivery to the central nervous system by crossing the blood-brain barrier. In preclinical studies presented at the RNA Leaders USA Congress 2025, ARO-MAPT demonstrated potent and sustained suppression of microtubule associated protein tau <a href=\"https://laohu8.com/S/MAPT\">$(MAPT)$</a> mRNA and tau protein in non-human primates. The company indicates that these results may enable monthly or quarterly dosing with uniform CNS distribution. Presentation slides are available on the Arrowhead website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208566889) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer’s Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer’s Disease\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-08 20:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer's Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arrowhead Pharmaceuticals Inc. announced the initiation of a Phase 1/2a clinical trial for ARO-MAPT, an investigational RNA interference (RNAi) therapeutic targeting tauopathies, including Alzheimer's disease. ARO-MAPT utilizes Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform, designed for subcutaneous administration and systemic delivery to the central nervous system by crossing the blood-brain barrier. In preclinical studies presented at the RNA Leaders USA Congress 2025, ARO-MAPT demonstrated potent and sustained suppression of microtubule associated protein tau <a href=\"https://laohu8.com/S/MAPT\">$(MAPT)$</a> mRNA and tau protein in non-human primates. The company indicates that these results may enable monthly or quarterly dosing with uniform CNS distribution. Presentation slides are available on the Arrowhead website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208566889) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票月供概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL7mDcF4:1","article_id":"2589330083","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589330083","pubTimestamp":1765197033,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Arrowhead Pharmaceuticals Inc. announced the initiation of a Phase 1/2a clinical trial for ARO-MAPT, an investigational RNA interference  therapeutic targeting tauopathies, including Alzheimer's disease. ARO-MAPT utilizes Arrowhead's proprietary Targeted RNAi Molecule  platform, designed for subcutaneous administration and systemic delivery to the central nervous system by crossing the blood-brain barrier. In preclinical studies presented at the RNA Leaders USA Congress 2025, ARO-MAPT demonstrated potent and sustained suppression of microtubule associated protein tau  mRNA and tau protein in non-human primates. The company indicates that these results may enable monthly or quarterly dosing with uniform CNS distribution. Presentation slides are available on the Arrowhead website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informati","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","ARWR":"Arrowhead Research Corporation","BK4139":"生物科技"},"translate_title":"Arrowhead Pharmaceuticals启动ARO-MAPT治疗阿尔茨海默病的1/2期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":0.9},"content_text":"Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer's Disease\n    \n\n        Arrowhead Pharmaceuticals Inc. announced the initiation of a Phase 1/2a clinical trial for ARO-MAPT, an investigational RNA interference (RNAi) therapeutic targeting tauopathies, including Alzheimer's disease. ARO-MAPT utilizes Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform, designed for subcutaneous administration and systemic delivery to the central nervous system by crossing the blood-brain barrier. In preclinical studies presented at the RNA Leaders USA Congress 2025, ARO-MAPT demonstrated potent and sustained suppression of microtubule associated protein tau $(MAPT)$ mRNA and tau protein in non-human primates. The company indicates that these results may enable monthly or quarterly dosing with uniform CNS distribution. Presentation slides are available on the Arrowhead website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208566889) on December 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}